BioSpace News Archive

Brexanolone IV submission is the Company’s first New Drug Application

Designation for the treatment of transthyretin (TTR)-mediated (ATTR) amyloidosis.

Posters presented at the Real World Dermatology for Physician Assistants and Nurse Practitioners conference also include data demonstrating test’s clinical utility

SHINE data illustrates SPINRAZA’s longer-term benefits for infantile-onset SMA, including improvements in motor function and increased event-free survival in participants followed for nearly three years

First-in-class online resource giving researchers access to patient-level clinical trial data from 14 of the world’s leading pharmaceutical companies across multiple therapeutic areas, today announced new strategic collaborations with four major non-profit partners

Project will increase capacity to meet growing customer demand

SCYNEXIS, Inc. announced data presented at the 28th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), April 21-24, 2018, in Madrid, Spain.

Patient Dosing Has Begun in First-in-Class Nitric Oxide Modulating, Microbiome-based Therapy

Kaleido Biosciences, a clinical-stage biotechnology company developing novel chemistries to unlock the power of the human microbiome, today announced the appointment of Joshua Brumm as chief financial officer.

MeiraGTx Limited, a vertically integrated, clinical stage gene therapy company, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for AAV-RPGR for the treatment of X-linked retinitis pigmentosa (XLRP) due to defects in the retinitis pigmentosa GTPase regulator (RPGR) gene.